Arcturus Therapeutics Holdings Inc. (ARCT) - 10-Q Summary
Business Context and Reporting Period
Company: Arcturus Therapeutics Holdings Inc.
Reporting Period: Quarter ended June 30, 2026 (Q2 2026).
Business Overview: Arcturus is a clinical-stage messenger RNA (mRNA) medicines company focused on liver and respiratory rare disease therapeutics (OTC deficiency, Cystic Fibrosis) and vaccines. The company developed KOSTAIVE, the world's first approved self-amplifying RNA (sa-mRNA) vaccine.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (in thousands) |
|---|---|
| Total Revenue | $5,020 |
| Net Loss | $(50,749) |
| Net Loss Per Share (Basic & Diluted) | $(1.79) |
| Research & Development Expenses | $39,042 |
| General & Administrative Expenses | $20,454 |
| Cash and Cash Equivalents (June 30, 2026) | $191,483 |
| Net Cash Used in Operating Activities | $(39,351) |
| Total Assets | $224,310 |
| Total Liabilities | $52,502 |
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased by 91% ($52.7 million) compared to the six months ended June 30, 2025. Collaboration revenue dropped 97% primarily due to reduced supply agreement revenue and amortization of deferred revenue as KOSTAIVE transitions to commercialization. Grant revenue decreased 54%.
- Expense Reduction: Total operating expenses decreased by 31% ($26.6 million). R&D expenses fell 39% driven by lower clinical trial and manufacturing costs for LUNAR-COVID, BARDA, and LUNAR-CF programs, alongside reduced headcount and share-based compensation.
- Loss Expansion: Net loss increased to $50.7 million from $23.3 million in the prior year period, reflecting the significant drop in revenue despite cost reductions.
- Liquidity: Cash and cash equivalents decreased by approximately $39.3 million during the period, primarily due to operating cash outflows.
Guidance, Outlook, and Material Events
- CSL Seqirus Termination (Subsequent Event): On August 3, 2026, Arcturus mutually terminated its Collaboration and License Agreement with CSL Seqirus.
- Financial Impact: Arcturus received a one-time cash payment of $12.0 million and was released from a liability/R&D credit of approximately $16.0 million.
- Strategic Impact: Arcturus regained strategic control of its vaccine portfolio (KOSTAIVE, influenza, RSV, EBV). Approximately $5.2 million in deferred revenue is expected to be recognized in Q3 2026.
- Obligations: Arcturus must pay single-digit royalties and revenue-sharing on future commercialization of these products where CSL IP is used.
- Thermo Fisher Agreement: In June 2026, Arcturus entered a strategic collaboration with Thermo Fisher for up to $40 million in clinical manufacturing services and up to $40 million in CRO services for the ARCT-032 (Cystic Fibrosis) program.
- Development Updates:
- LUNAR-CF (ARCT-032): Phase 2 trial ongoing; fourth cohort enrolling with 12-week dosing to assess long-term safety and efficacy.
- LUNAR-OTC (ARCT-810): Phase 2 enrollment completed; evaluating data for End-of-Phase 2 meeting.
- Liquidity Outlook: Management believes current cash resources are sufficient to fund operations for at least the next 12 months. Future capital requirements depend on clinical progress and commercialization of KOSTAIVE.
Investor Verification Checklist
- CSL Termination Terms: Verify the specific royalty rates and revenue-sharing caps applicable to the regained vaccine portfolio.
- Deferred Revenue Recognition: Confirm the timing and amount of the $5.2 million deferred revenue recognition in Q3 2026.
- Thermo Fisher Funding: Assess the conditions required to unlock the $40 million in manufacturing and CRO services for ARCT-032.
- Cash Burn Rate: Monitor the net cash used in operating activities to ensure the 12-month runway remains valid given the loss of CSL collaboration revenue.
- Legal Proceedings: Review the status of the trade secret misappropriation lawsuit against AbbVie and Capstan Therapeutics.